Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00036764 · ClinicalTrials.gov registry record · Phase 2

BMS-247550 in Treating Patients With Stage IV Melanoma

A Phase 2 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
88
Enrollment target

NCT00036764: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).

NCT00036764 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 88 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add start date to calendar (.ics) →

The verdict

NCT00036764, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
88 participants
Enrollment target

Study Summary

Phase II trial to study the effectiveness of BMS-247550 in treating patients who have stage IV melanoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Primary Outcome

The 95% confidence intervals will be provided.

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER pharmacogenomic studies
  • DRUG ixabepilone

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2002-02
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00036764 record still lists

NCT00036764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower).

The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.

NCT00036764 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00036764 about?

NCT00036764 is a clinical study titled "BMS-247550 in Treating Patients With Stage IV Melanoma". Phase II trial to study the effectiveness of BMS-247550 in treating patients who have stage IV melanoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

What is the current status of trial NCT00036764?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2002-02.

What interventions are being tested in trial NCT00036764?

The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacogenomic studies (OTHER), ixabepilone (DRUG).

Who is sponsoring clinical trial NCT00036764?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00036764's enrollment target sits among peer trials

88 803rd of 2000 higher than 1,191 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03843463 · 88 participants · Phase 2

    Escitalopram and Language Intervention for Subacute Aphasia

  • NCT04066348 · 88 participants · Phase 2

    TNF-α Treatment of Blast-Induced Tinnitus

  • NCT04331704 · 88 participants · Phase 4

    ANCHORS Alcohol & Sexual Health Study: UH3 Project

  • NCT04536103 · 88 participants

    Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00036764, the US trial registry maintained by the National Library of Medicine. NCT00036764 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.